BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Sandoz (SDZ.SW) reported first quarter net sales of $2.76 billion compared to $2.48 billion, prior year. Sandoz said its performance was in line with company expectations. The company confirmed its guidance for 2026.
Overall net sales were up by 3% at CC, and by 5% when excluding effect of adverse dynamics in anti-infective B2B business. Biosimilar net sales were up by 18% at CC, with generics net sales declining by 3% at CC. Underlying generics net sales declined by 1% at CC when excluding anti-infective B2B impact.
The company intends to publish half-year results on 5 August 2026.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
